Fuzuloparib, Abiraterone acetate and Prednisone

Phase 3

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

JHPCYPhase 3$38.2B

Fuzuloparib, Abiraterone acetate and Prednisone Phase 3 Est. Readout

Fuzuloparib, Abiraterone acetate and Prednisone• Metastatic Castration-Resistant Prostate Cancer (mCRPC)496

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

View Full Landscape

Drug Information

Target Indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trial

NCT04691804

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

Camrelizumab plus TPPhase 3

Oral Squamous Cell Carcinoma

Apatinib MesylatePhase 3

Hepatocellular Carcinoma

Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxelPhase 3

Breast Cancer Invasive

SHR8554 InjectionPhase 3

Pain

INS068 injectionPhase 3

Type 2 Diabetes Mellitus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts